(GENI) Generic Sweden publ - Ratings and Ratios
Exchange: ST • Country: Sweden • Currency: SEK • Type: Common Stock • ISIN: SE0001790791
GENI EPS (Earnings per Share)
GENI Revenue
GENI: Messaging, Communication, Technology, Solutions, Platforms
Generic Sweden AB is a Swedish technology company specializing in messaging services and digital communication platforms. With a history dating back to 1993, the company has established itself as a key player in the IT consulting and services sector, headquartered in Stockholm, Sweden. For more information, visit their official website at https://www.generic.se. As a provider of messaging services for various applications, Generic Sweden ABs offerings cater to a broad range of digital communication needs.
Analyzing the companys stock, GENI, we observe that it is classified as a common stock under the GICS Sub Industry of IT Consulting & Other Services, originating from Sweden. This categorization places Generic Sweden AB within a specific investment universe, allowing for more targeted comparisons and analyses.
By examining the technical indicators, we can infer potential trends and price movements. Given the current Last Price of 55.80 SEK, the stock is below its SMA20 (58.88 SEK) and SMA50 (57.96 SEK), indicating a potential short-term downtrend. However, it remains above its SMA200 (51.75 SEK), suggesting a longer-term uptrend. The ATR of 1.98 SEK (or 3.55%) signifies moderate volatility. With the 52-week high and low at 61.80 SEK and 40.84 SEK, respectively, the stock is currently trading near the middle of its recent range. Combining these technical insights with fundamental data, such as a Market Cap of 737.52M SEK, a P/E ratio of 24.96, and a RoE of 57.88%, we can forecast the stocks potential performance.
Forecasting the stocks future movement involves integrating both technical and fundamental analyses. The relatively high RoE of 57.88% indicates strong profitability, which, combined with a P/E ratio of 24.96, suggests that the stock might be fairly valued or slightly overvalued, depending on future earnings growth expectations. Technically, a break above the SMA20 and SMA50 could signal a resumption of the uptrend, potentially targeting the 52-week high of 61.80 SEK. Conversely, failure to break through these resistance levels might lead to a retest of the SMA200 or lower. Therefore, a likely forecast is that GENI will experience a short-term correction or consolidation before potentially resuming its longer-term uptrend, driven by its strong fundamental performance.
Additional Sources for GENI Stock
GENI Stock Overview
Market Cap in USD | 76m |
Sector | Technology |
Industry | Software - Application |
GiC Sub-Industry | IT Consulting & Other Services |
IPO / Inception |
GENI Stock Ratings
Growth Rating | 55.1 |
Fundamental | 78.4 |
Dividend Rating | 77.4 |
Rel. Strength | 7.09 |
Analysts | - |
Fair Price Momentum | 55.62 SEK |
Fair Price DCF | 23.02 SEK |
GENI Dividends
Dividend Yield 12m | 3.06% |
Yield on Cost 5y | 9.54% |
Annual Growth 5y | 37.97% |
Payout Consistency | 98.0% |
Payout Ratio | 67.0% |
GENI Growth Ratios
Growth Correlation 3m | 40.4% |
Growth Correlation 12m | 84% |
Growth Correlation 5y | 23% |
CAGR 5y | 26.80% |
CAGR/Max DD 5y | 0.36 |
Sharpe Ratio 12m | -0.13 |
Alpha | 12.76 |
Beta | 0.634 |
Volatility | 35.93% |
Current Volume | 36.4k |
Average Volume 20d | 23.4k |
As of June 25, 2025, the stock is trading at SEK 55.10 with a total of 36,430 shares traded.
Over the past week, the price has changed by -3.16%, over one month by -10.70%, over three months by -2.96% and over the past year by +22.67%.
Yes, based on ValueRay´s Fundamental Analyses, Generic Sweden publ (ST:GENI) is currently (June 2025) a good stock to buy. It has a ValueRay Fundamental Rating of 78.44 and therefor a positive outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of GENI is around 55.62 SEK . This means that GENI is currently overvalued and has a potential downside of 0.94%.
Generic Sweden publ has no consensus analysts rating.
According to our own proprietary Forecast Model, GENI Generic Sweden publ will be worth about 62.1 in June 2026. The stock is currently trading at 55.10. This means that the stock has a potential upside of +12.74%.
Issuer | Target | Up/Down from current |
---|---|---|
Wallstreet Target Price | 5.6 | -89.9% |
Analysts Target Price | - | - |
ValueRay Target Price | 62.1 | 12.7% |